Femasys Inc. (FEMY) Valuation — DCF, Graham & Comparables

Femasys Inc. (FEMY) — Price $2.54 HealthcareMedical - Instruments & Supplies — NASDAQ

Latest reported results:

Valuation dashboard for Femasys Inc. (FEMY) with P/E N/A, P/B N/A, EV/EBITDA N/A and dividend yield N/A. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.

Femasys Inc., a biomedical company established in 2004 and based in Suwanee, Georgia, primarily targets the women's healthcare market within the United States. The firm's innovative product line includes permanent contraceptive solutions such as FemBloc and FemChec, alongside FemaSeed, which is an artificial insemination offering.

Analysis Summary

Femasys Inc. reported revenue of $2.3M in the most recent fiscal year, growing at a 5-year CAGR of 17.2%.

Balance sheet quality for FEMY: current ratio of 4.5. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.

Peer Comparison

SymbolCompanyMarket CapP/EP/BROE
FEMYFemasys Inc.$8M
0R29.LIntuitive Surgical, Inc.$135.9B74.0511.8617.8%
ISRGIntuitive Surgical, Inc.$135.1B44.137.6217.8%
0R19.LBecton, Dickinson and Company$52.5B33.212.196.6%
BDXBecton, Dickinson and Company$50.1B55.542.083.8%
RMDResMed Inc.$33.1B22.815.2323.9%
0KW4.LResMed Inc.$32.5B19.304.4723.1%
MDLNMedline Inc.$27.9B38.362.445.4%

Price

Price$2.54
Market Cap$8M
ExchangeNASDAQ
CountryUS

Related companies: AIMD · APLM · BCTX · COCH · CRIS · DARE · EKSO

Explore sector: Healthcare · Medical - Instruments & Supplies

More sections of FEMY: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events

Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks